Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases

Journal of Controlled Release

Volumn 127, Issue 1, 2008, Pages 70-78

  Tang, Yiqing ^a   Czuczman, Peter R ^a   Chung, Shui T ^a   Lewis, Andrew L ^a  

^a BIOCOMPATIBLES UK LTD   (United Kingdom)

Author keywords

Colorectal cancer metastases; Drug eluting beads; Irinotecan; Lactone form

Indexed keywords

DRUG INTERACTIONS; DRUG THERAPY; HYDROGELS; POLYVINYL ACETATES;

COLORECTAL CANCER METASTASES; DRUG ELUTING BEADS; IRINOTECAN; LACTONE FORM;

ONCOLOGY;

IRINOTECAN; LACTONE;

ARTICLE; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEL; HYDROLYSIS; LACTONIZATION; METASTASIS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; HYDROGELS; HYDROGEN-ION CONCENTRATION; KINETICS; LACTONES; LIVER NEOPLASMS; MICROSPHERES; MODELS, CHEMICAL; PARTICLE SIZE; SOLUBILITY;

EID: 40649123230     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.12.012     Document Type: Article

References (30)

1. Mathijssen R.H.J., van Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., and Sparrboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7 (2001) 2182-2194
2. Burke T.G., and Mi Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal. Biochem. 212 (1993) 285-287
3. Mi Z., and Burke T.G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33 (1994) 10325-10336
4. Chou T.-H., Chen S.-G., and Chu I.-M. Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method. J. Biosci. Bioeng. 95 (2003) 405-408
5. Drummond D.C., Noble C.O., Guo Z., Hong K., Park J.W., and Kirptin D.B. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 66 (2006) 3271-3277
6. Boyd B.J., Whittaker D.V., Khoo S.-M., and Davey G. Hexosomes formed from glycerate surfactants-formulation as a colloidal carrier for irinotecan. Int. J. Pharm. 318 (2006) 154-162
7. Machida Y., Onishi H., Morikawa A., and Machida Y. Antitumour characteristics of irinotecan-containing microspheres of poly-d,l-lactic acid or poly(d,l-lactic acid-co-glycolic acid) copolymers. S.T.P. Pharm. Sci. 8 (1998) 175-181
8. Onishi H., Machida Y., and Machida Y. Antitumor properties of irinotecan-containing nanoparticles prepared using poly(dl-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol). Biol. Pharm. Bull. 26 (2003) 116-119
9. Lewis A.L., Gonzalez M.V., Lloyd A.W., Hall B., Tang Y., Willis S.L., Leppard S.W., Wolfenden L.C., Palmer R.R., and Stratford P.W. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J. Vasc. Interv. Radiol. 17 (2006) 335-342
10. Taylor R.R., Tang Y., Gonzalez M.V., Stratford P.W., and Lewis A.L. Irinotecan drug eluting beads for use in chemo-embolization: in vitro and in vivo evaluation of drug release properties. Eur. J. Pharm. Sci. 30 (2007) 7-14
11. Varela M., Real M.I., Burrel M., Forner A., Sala M., Brunet M., Ayuso C., Castells L., Montañá X., Llovet J.M., and Bruix J. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J. Hepatol. 46 (2007) 474-481
12. Aliberti C., Tilli M., Benea G., and Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res. 26 (2006) 3779-3782
13. Dodds H.M., Craik D.J., and Rivory L.P. Photodegradation of irinotecan (CPT-11) in aqueous solutions: identification of fluorescent products and influence of solution composition. J. Pharm. Sci. 86 (1997) 1410-1416
14. Amyot F., Jurski K., Dufaux J., and Guiffant G. An experimental and theoretical study of mass transfer from loaded embolisation microbeads: possible optimization. Int. Comm. Heat Mass Transf. 29 (2002) 623-632
15. Amyot F., Boudy V., Jurski K., Counord J.-L., Guiffant G., Dufaux J., and Chaumeil J.-C. A new experimental method for the evaluation of the release profiles of drug-loaded microbeads designed for embolisation. ITBM RBM 23 (2002) 285-289
16. Fassberg J., and Stella V.J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 81 (1992) 676-684
17. Evans N.D., Errington R.J., Shelley M., Feeney G.P., Chapman M.J., Godfrey K.R., Smith P.J., and Chappell M.J. A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan. Math. Biosci. 189 (2004) 185-217
18. Reichenberg D. Properties of ion-exchange resins in relation to their structure. III. Kinetics of exchange. J. Am. Chem. Soc. 75 (1953) 589-597
19. Boyd G.E., Adamson A.W., and Myers L.S. The exchange adsorption of ions from aqueous solutions by organic zeolites. II. Kinetics. J. Am. Chem. Soc. 69 (1947) 2836-2848
20. Predicted property values for registry number: 97682-44-5, irinotecan, SciFinder(r) 2007 database, American Chemical Society. Calculated using Advanced Chemistry Development (ACD/Labs) Software V8.14 for Solaris (© 1994-2007 ACD/Labs).
21. Lewis A.L., Gonzalez M.V., Leppard S.W., Brown J.E., Stratford P.W., Phillips G.J., and Lloyd A.W. Doxorubicin eluting beads - 1: effects of drug loading on bead characteristics and drug distribution. J. Mater. Sci., Mater. Med. 18 (2007) 1691-1699
22. Akimoto K., Kawai A., and Ohya K. Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous solution. Chem. Pharm. Bull. 42 (1994) 2135-2138
23. Chretien C., Boudy V., Allain P., and Chaumeil J.C. Indomethacin release from ion-exchange microspheres: impregnation with alginate reduces release rate. J. Control. Release 96 (2004) 369-378
24. Liu Z., Cheung R., Wu X.Y., Ballinger J.R., Bendayan R., and Rauth A.M. A study of doxorubicin loading onto and release from sulfopropyl dextran ion-exchange microspheres. J. Control. Release 77 (2001) 213-224
25. M.V. Gonzalez, PhD thesis, University of Brighton, 2006.
26. Fleury F., Kudelina I., and Nabiev I. Interactions of lactone, carboxylate and self-aggregated forms of camptothecin with human and bovine serum albumins. FEBS Lett. 406 (1997) 151-156
27. Fleury F., Ianoul A., Berjot M., Feofanov A., Alix A.J.P., and Nabiev I. Camptothecin-binding site in human serum albumin and protein transformations induced by drug binding. FEBS Lett. 411 (1997) 215-220
28. Prijovicha Z.M., Leub Y.-L., and Rofflera S.R. Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin. Biochem. Pharmacol. 66 (2003) 1181-1187
29. Machida Y., Onishi H., Kurita A., Hata H., Morikawa H., and Machida Y. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats. J. Control. Release 66 (2000) 159-175
30. Gerrits C.J., de Jonge M.J., Schellens J.H., Stoter G., and Verweij J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br. J. Cancer 76 (1997) 952-962